Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the blood pharmacokinetics in patients with previously
untreated or relapsed follicular or transformed follicular non-Hodgkin's lymphoma who have
received a dosimetric dose of fission-derived iodine I 131 tositumomab.